tbuckley/cabot-search huggingface dataset:
Association of American Medical Colleges.
Authors: Dudley S. Reynolds
Journal: JAMA (1900)

Chicago, Feb. 10, 1900. <h3>To the Editor:</h3> —The Association of American Medical Colleges ought to sustain the regular classical and scientific courses of the university and under no circumstances encourage students to leave the university to begin professional study before graduating. If the college curriculum is not worth while to the student, it is a matter for the university authorities to correct. The judicial council has lately passed the following judgment in relation to the application of one of these universities. <h3>ANSWER TO INTERROGATORIES PROPOUNDED BY THE WEST VIRGINIA UNIVERSITY.</h3> The Judicial Council of the Association of American Medical Colleges assumes that the premedical course is provided for students who contemplate studying medicine. The subjects announced for the premedical course being included with those studies leading to the bachelor's degree would entitle the graduates of the West Virginia University to enter the second year's course in a regular medical school.
Measles Outbreak Among Internationally Adopted Children Arriving in the United States, February-March 2001
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cognitively Impaired Older Drivers, Risk Assessment, and Physician Responsibility—Reply
Authors: Lisa J. Molnar
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nocardia asteroides sinusitis. Presentation as a trimethoprim-sulfamethoxazole responsive fever of unknown origin
Authors: P. Katz
Journal: JAMA (1977)

A patient with a yearlong fever of unknown origin responded to trimethoprim-sulfamethoxazole and was discovered to have culture-proved<i>Nocardia asteroides</i>sinusitis, with absence of detectable disease in other organs. An inhalational route is postulated as the mode of entry of the organism, with localization in the maxillary sinus. <i>JAMA</i>238:2397-2398, 1977)
Use of Laboratory Tests for Immune Biomarkers in Environmental Health Studies Concerned with Exposure to Indoor Air Pollutants
Authors: Robert F. Vogt
Journal: Environmental Health Perspectives (1991)

The immune system is likely to be involved in some of the health effects caused by certain indoor air exposures, and immune biomarkers can help determine which exposures and health effects have important immune components. However, the lack of standardized laboratory tests for most human immune markers and the many confounding variables that can influence them makes interpretation of results for exposure and disease end points uncertain. This paper presents an overview of the immune system and the considerations involved in using tests for immune markers in clinical epidemiology studies, particularly those concerned with indoor air exposures. Careful study design, well-characterized laboratory methods, and rigorous documentation of exposure status are required to determine the predictive value of such tests. Clinical tests currently available for some immune markers could help identify and characterize both irritative and hypersensitivity reactions to indoor air pollutants. Newer tests developed in research settings might provide more incisive indicators of immune status that could help identify exposure, susceptibility, or preclinical disease states, but their methodologies must be refined and tested in multicenter studies before they can be used reliably in public health applications.
Error in Supplement
Journal: JAMA Network Open (2019)

In the Original Investigation titled "Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy," 1 published August 10, 2018, there was an error in the column heads of eTable 7 in the Supplement.In both eTable 7a and 7b, the left column head should have read "Lumpectomy alone" and the right, "Lumpectomy and radiation."The headers were inadvertently switched.This article has been corrected. 1
Medicare DOGs
Authors: Stanley Wohl
Journal: JAMA (1987)

It's taken me a few years, but I've finally secured a handle on this Medicare DOG system. My function, as I now understand it, is to push Medicare patients in and out of the hospital rapidly, without wasting any money by treating them. My goal is to keep them just long enough to allow the hospital DOG analyst to pin a DOG number on the chart. The hospital makes its money as soon as the DOG number is assigned. It's absolutely brilliant. Why couldn't I have thought of it? You could just about lose your lunch when you consider how wasteful we used to be before we had DOGs to guide us. Before 1983 we used to admit the elderly to hospitals and treat them before discharge: incredible fiscal irresponsibility! We used to spend hours in the operating room trying to alleviate suffering: spend, spend, spend. We were nothing but
Correction
Journal: Annals of the Rheumatic Diseases (2010)

incidence, but a consequence of postponed onset due to the immunosuppressive properties of pregnancy.More research is needed to study these issues in arthritic and other autoimmune diseases.In summary, the proportion of incident cases with onset 0-24 months after delivery, were not different for RA and OCA.A peak in onset of disease 0-24 months versus 25-48 months post partum was seen overall and in the RA group, both for the total number of pregnancies and for diagnosis after the first pregnancy.
Cluster mannosides can inhibit mannose receptor-mediated tissue-type plasminogen activator degradation by both rat and human cells
Authors: F Noorman, M M Barrett-Bergshoeff, E A L Biessen, E van de Bilt, T J C van Berkel, D C Rijken
Journal: Hepatology (1997)

Recently, we developed a series of cluster mannosides that were able to inhibit tissue-type plasminogen activator (t-PA) binding to the isolated mannose receptor. The mannoside with the highest affinity was able to inhibit t-PA clearance by the liver in the rat. To test whether these mannosides would also be efficient inhibitors in humans, we studied the expression of the mannose receptor in the human liver and determined the efficacy of the mannosides to inhibit mannose receptor-mediated t-PA degradation by both rat and human cells. Immunohistochemistry indicates that, like the rat, human liver endothelial cells and human Kupffer cells do express the mannose receptor. The mannosides do inhibit mannose receptor-mediated t-PA binding, association, and degradation by isolated rat liver endothelial cells and t-PA association and degradation by cultured human macrophages at similar concentrations. The cluster mannoside with six mannose residues connected with a backbone of five lysine groups (M 6 L 5 ) was, like unlabeled t-PA, able to inhibit 125 I-t-PA degradation in the nmol/L range, while the mannoside M 5 L 4 inhibited 125 I-t-PA degradation in the μmol/L range. The concentrations of mannoside necessary to inhibit 125 I-t-PA degradation in vitro were comparable with the concentrations necessary to inhibit mannose receptor-mediated 125 I-t-PA clearance in vivo . We conclude that there is no species difference between rat and humans with respect to the distribution of the mannose receptor in the liver and the affinity of the cluster mannosides, establishing the relevance of the inhibition of mannose receptor- mediated t-PA clearance by M 6 L 5 as observed in the rat, for the human situation.
Abandoned Homestead
Authors: M. Therese Southgate
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reference Citation Error
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ORTHOPEDIC WRENCH
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE YELLOW FEVER.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Microbiological investigation of a hospital outbreak of invasive group A streptococcal disease in Krakow, Poland
Authors: Magdalena Strus, Artur Drzewiecki, Agnieszka Chmielarczyk, Anna Tomusiak, PaweÅ Romanek, Krzysztof Kosowski, Piotr Kochan, Mark van der Linden, Rudolf LÃ¼tticken, Piotr B. Heczko
Journal: Clinical Microbiology and Infection (2009)
North American (NA) subgroup results from VELOUR: Ziv-aflibercept versus placebo (pbo) plus FOLFIRI in mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen.
Authors: Edith P. Mitchell, Michael J. Guarino, Carmen Joseph Allegra, Emmanuelle Boelle, Michael L. Andria, Pankaj Bhargava, Jeffrey J. Kirshner
Journal: Journal of Clinical Oncology (2013)

465 Background: Ziv-aflibercept (trade name ZALTRAP; known outside the US as aflibercept) is a new multiple angiogenic inhibitor that prevents VEGF-A, VEGF-B and PLGF from binding their receptors. Ziv-aflibercept was recently approved by the FDA in combination with FOLFIRI for patients with mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen. Approval was based on the multinational phase III VELOUR trial (N=1226) which showed statistically significant improvements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) with aflibercept + FOLFIRI. Detailed analyses of the NA subgroup are presented here. Methods: Patients were randomized 1:1 to ziv-aflibercept (4 mg/kg) + FOLFIRI or pbo + FOLFIRI every 2 wk. Patients had ECOG performance status (PS) ≤2, 1 prior oxaliplatin-based regimen, and prior bevacizumab (bev) was allowed. Primary endpoint was OS. The NA analysis was pre-specified, but not powered, to compare within or between subgroups. Results: NA patients (N=138) were randomized to ziv-aflibercept + FOLFIRI (n=63) or pbo + FOLFIRI (n=75). Baseline characteristics were similar in both arms (ziv-aflibercept: median 61 yrs; 60% male; 96% PS 0-1; 56% &gt;1 metastatic organ; 74% prior bev). Ziv-aflibercept vs pbo improved median OS (17.94 vs 12.88 mos; HR=0.691, 95% CI: 0.442-1.079), median PFS (6.01 vs 4.17 mos; HR=0.536, 99.9% CI: 0.222-1.296) and ORR (12% vs 9%). Patients on average received more cycles (median 8.5 vs 7.0) and had longer duration of exposure (median 20 vs 14 wk), but had more treatment modifications with ziv-aflibercept vs pbo. Most of the severe AEs (grade ≥3) with ziv-aflibercept were grade 3 including hypertension, venous thromboembolic events, proteinuria, diarrhea, fatigue/asthenia, infection, stomatitis/ulceration and neutropenia. There were few grade 4 AEs. Conclusions: Ziv-aflibercept + FOLFIRI in NA mCRC patients previously treated with an oxaliplatin-based regimen (with or without prior bev) resulted in improved OS, PFS, and ORR, with an acceptable safety profile. The NA results are consistent with the VELOUR worldwide population. Clinical trial information: NCT00561470.
Gray Areas
Authors: Alia Moore
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of psoriasis with intermittent short course cyclosporin (Neoral<sup>®</sup>). A multicentre study
Authors: J. BERTH-JONES, C.A. HENDERSON, C.S. MUNRO, S. ROGERS, R.J.G. CHALMERS, M.J. BOFFA, P.G. NORRIS, P.S. FRIEDMANN, R.A.C GRAHAM-BROWN, P.M. DOWD, R. MARKS, M.J. SUMNER
Journal: British Journal of Dermatology (1997)
For Some of Nation's Young Athletes, Training May Be Too Much of a Good Thing
Authors: Virginia S. Cowart
Journal: JAMA (1989)

WHILE MANY, if not most, Americans fail to exercise enough, a young subgroup of the population is overdoing it. As elite sports programs for child athletes multiply, sports medicine physicians say some youngsters simply take on more than their bodies can handle. Additional problems arise because of inadequate training or safety precautions or because of unrecognized preexisting medical conditions. Lyle J. Micheli, MD, president of the American College of Sports Medicine, has a special interest in the child athlete. "We actually have a double problem," he says. "On the one hand, there are children who don't exercise enough to be healthy. Then there is a smaller group of children who get too much exercise." Micheli is director, Division of Sports Medicine, Children's Hospital Medical Center, Boston, Mass. He says injuries are being reported in children that were not seen in the past, occurring now mostly because of overexercising. <h3>Some Cases</h3>
Anti-HIV substances for rape victims
Authors: S. Murphy
Journal: JAMA (1989)

<h3>To the Editor.—</h3> We agree with Foster and Bartlett<sup>1</sup>that physicians involved in the assessment, treatment, and counseling of rape victims should have a management policy that includes the possibility of human immunodeficiency virus (HIV) infection acquired during the sexual assault. Our current practice is to take a sample of serum for storage, at the initial presentation, with a view to subsequent testing, if required. We then discuss HIV testing 3 months later following HIV pretest counseling to allow documentation of HIV seroconversion should it occur. Given that HIV seroconversion may be more prolonged, subsequent testing may be considered in certain cases. The risk of acquiring HIV during rape is unknown, and to date there is no effective vaccine or prophylaxis against HIV. To suggest the routine topical administration of nonoxynol 9 or vinegar by the physician or by the victim herself (or himself) is surely premature, and perhaps
Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia
Authors: Jackie Boultwood, Carrie Fidler, Patricia Shepherd, Fiona Watkins, Joanna Snowball, Sara Haynes, Rajko Kusec, Alex Gaiger, Timothy J. Littlewood, Andrew J. Peniket, James S. Wainscoat
Journal: American Journal of Hematology (1999)

We studied telomere length in the peripheral blood leukocyte samples of a large group of patients with chronic myelogenous leukemia (CML) by Southern blot hybridization using the (TTAGGG)4 probe. The average telomere length expressed as the peak telomere repeat array (TRA) of the peripheral blood samples obtained from a group of 34 healthy age-matched controls ranged between 7.6 and 10.0 kb and the mean peak TRA was 8.7 kb. Forty-one patients in the chronic phase of CML were studied; 32/41 (78%) showed telomere reduction (<7.6 kb) relative to age-matched controls and the mean peak TRA was 6.4 kb (range 4.0–10.6 kb). Serial samples were analysed from 12 patients at both chronic phase and during disease progression. The leukocyte DNA of all 12 patients in accelerated phase and/or blast crisis showed telomere reduction relative to age-matched controls and the mean peak TRA was 4.1 kb (range 3.0–5.4 kb). The peak TRA in the accelerated or blast phase was reduced compared with the corresponding paired sample in the chronic phase in all cases studied. These data show that a marked reduction in telomere length is associated with disease progression in CML. Am. J. Hematol. 61:5–9, 1999. © 1999 Wiley-Liss, Inc.